Barinthus Biotherapeutics PLC - ADR, formerly Vaccitech PLC, is a biotechnology company that specializes in the development of vaccines and immunotherapies for infectious diseases and cancer. The company was founded in 2016 by Professor Sarah Gilbert and Dr. Adrian Hill, both from the University of Oxford, along with a team of scientists and entrepreneurs. The founders of Vaccitech were involved in the development of the Oxford-AstraZeneca COVID-19 vaccine, which brought significant recognition to the company.
Vaccitech's primary focus is on using its proprietary platform technology to develop novel T cell immunotherapies and vaccines. The platform, known as the chimpanzee adenovirus Oxford (ChAdOx), is designed to stimulate a strong and targeted immune response in patients. The company's pipeline includes vaccines for infectious diseases such as MERS (Middle East Respiratory Syndrome) and HPV (Human Papillomavirus), as well as immunotherapies for various cancer types.
Vaccitech's ChAdOx platform has been licensed to several companies, including AstraZeneca, for the development of vaccines and immunotherapies. The company collaborates with pharmaceutical and biotechnology partners to advance its programs and bring potential treatments to patients worldwide.
In addition to its COVID-19 vaccine collaboration, Vaccitech has entered into partnerships to explore the potential of its platform in addressing other infectious diseases and cancer. The company's commitment to advancing innovative solutions in the field of immunotherapy has drawn attention from investors and the medical community alike.